Articles tagged with Osteoporosis
A new study questions the use of estrens as estrogen-like molecules for treating osteoporosis. Estrens improved bone strength in mice, but also caused adverse effects on reproductive organs and human breast cancer cells. Further clinical trials are needed to determine their safety.
A new study recruiting up to 2,000 people from the remote Isles of Orkney aims to discover genes that predispose individuals to osteoporosis. The research will utilize a unique population isolated from the UK mainland, allowing for easier tracking and identification of genetic factors.
Researchers reveal that glucocorticoids, commonly used for inflammatory disorders, can cause osteoporosis by delaying osteoclast death and suppressing bone formation. Prolonged GC use affects bone health in mice with normal and disrupted GC receptors.
A study by family doctors found that women taking a monthly tablet of ibandronate and receiving telephone support showed a 47% greater persistence with their medication than those on weekly alendronate. This improved compliance is crucial in treating osteoporosis, which affects one in three women over 50 worldwide.
Researchers have identified a protein in mice that regulates bone formation, finding that augmented osteoblast activity leads to elevated bone mass. The discovery could lead to new treatments for osteoporosis by targeting the Shn3 and WWP1 proteins.
The number of hip fractures worldwide is projected to rise from 1.7 million in 1990 to 6.3 million in 2050, with estimated annual costs reaching $131.5 billion globally and $30 billion in the EU.
A new study by Stanford Medicine researchers found that the first osteoporosis medication, teriparatide, is not cost-effective compared to alendronate. The researchers suggest that teriparatide should be given only to high-risk patients who don't tolerate standard treatments.
Researchers found that orange and grapefruit juice can increase antioxidants in rats' systems, leading to enhanced bone density. The study suggests a potential link between citrus consumption and improved bone health.
Significant studies presented at the World Congress on Osteoporosis highlight the importance of calcium, vitamin D, and protein in building bones, as well as the impact of space travel, obesity, and smoking on bone health. The congress also emphasized the need for improved screening and treatment options for osteoporosis patients.
Seven young researchers from six countries have been awarded the IOF-Novartis Young Scholars' Award for outstanding contributions to osteoporosis research. The award aims to support and encourage careers in osteoporosis research, a field that has seen significant progress in understanding and treating this debilitating disease.
Studies in Sweden, China, and the US find strong links between smoking and osteoporosis, with smoking hastening bone erosion and increasing fracture risk. Second-hand smoke also significantly increases risk for osteoporosis and fractures in both men and women.
Dr Elise Feng-I Morgan, a researcher at Boston University, has been awarded the 2005 IOF-Servier Young Investigator Award for her innovative research on osteoporosis. This prestigious award aims to promote awareness and understanding of osteoporosis among young scientists.
A new study reveals that dietary calcium is more beneficial than supplements alone for building strong bones. Vitamin D supplements only reduce fracture risk when combined with sufficient calcium levels. Meanwhile, research suggests high protein intake promotes bone health.
Researchers found that leisure activity levels significantly impact bone mass increase in children and adolescents, with more intense physical activity leading to greater increases in bone density. Exercise during childhood is crucial for optimal bone accrual and reducing the risk of osteoporosis later in life.
The 2nd IOF Women Leaders Roundtable emphasizes the need for global awareness and action on osteoporosis. The participants urge individuals to engage in bone-friendly lifestyles and healthcare professionals to improve their knowledge about osteoporosis, while governments are encouraged to recognize it as a health priority.
A new model predicts osteoporosis risk by integrating age, height, weight, and other factors, identifying susceptible individuals for targeted treatment. Researchers also found that obesity accelerates bone loss, contradicting prior assumptions, and that certain medications like SSRIs may increase fracture risk.
A new study reveals a growing osteoporosis crisis in Latin America, with higher prevalence rates than expected. The study's findings highlight the need for increased attention and funding from governments to address this growing health issue. In contrast, North American diagnosis and treatment of osteoporosis are influenced by socioeco...
A recent study found that osteoporosis is widely underdiagnosed and undertreated, with many patients stopping their prescribed medication prematurely. Low trauma fractures are often an indication of osteoporosis, but patients may not receive adequate screening or education on managing the condition.
Rates of hip bone loss increase with age among white and non-white men, particularly those over 75. Osteoporosis in men results from declining estrogen levels, leading to brittle bones prone to fracture. The study predicts a 56% increase in male osteoporotic fractures and associated costs by 2025.
Research suggests that infant bone growth and maternal vitamin D levels during pregnancy have a significant impact on future fracture risk. Children born to mothers with lower vitamin D levels tend to have weaker bones, while higher levels may improve bone density.
Studies reveal that age-related changes in bone geometry and architecture can lead to increased fracture risk. Researchers found that older women experience a decrease in dense spongy tissue and an increase in cortical bone thickness, but not overall bone density.
A study found that annual rates of hip fracture among Swiss female nursing home residents decreased by 1.3% per year during the 1990s. This decrease was linked to improved prescription of calcium and vitamin D, as well as enhanced preventative care regarding risk factors for falls.
Research suggests strontium ranelate strengthens bone architecture for at least five years, reducing fracture risk. Bisphosphonates remain effective for extended periods, but may pose risks to young patients with osteoporosis.
The International Osteoporosis Foundation (IOF) has partnered with Tetra Pak to support World Osteoporosis Day. The partnership aims to empower women and men to take responsibility for their bone health. World Osteoporosis Day, celebrated on October 20, highlights the importance of healthy food and nutrition in building strong bones.
A growing body of research suggests that lead exposure in childhood accelerates bone growth, but ultimately prevents optimal peak bone mass, increasing the risk of osteoporosis and fractures. Clinical study aims to better understand the role of lead in bone development and loss.
A new study suggests a calcium phosphate-based supplement improves bone strength and thickness in rats with mineral deficiency-induced osteoporosis. The Mg/Zn/F-CaP supplement showed substantial improvement in bone properties without the side effects of current pharmaceutical treatments.
Researchers found that denosumab significantly increased BMD at the total hip (3.6% vs. -0.6%) and lumbar spine (6.7% vs. -0.8%) in women administered the therapy twice yearly, with a rapid onset of action. The study also showed improvements in distal 1/3 radius and total body BMD.
A phase 2 trial evaluating denosumab, a RANK Ligand inhibitor, found the treatment increased BMD at the lumbar spine and total hip in postmenopausal women with low BMD. The therapy demonstrated rapid and sustained responses in bone metabolism.
A large European study found that a top candidate gene variant does not significantly increase the risk of osteoporosis, contrary to previous research. The study, which involved over 20,000 participants, suggests that genetic testing for this variant alone is not sufficient to accurately predict fracture risk.
Researchers at the University of Alberta have developed a guide for doctors to assess height loss and determine if it's related to vertebral fractures or osteoporosis. The guidelines suggest prescribing X-rays for patients who lose six centimeters in height, as this is associated with a 60% chance of vertebral fractures.
The study found a small but significant increase in hip bone density among women taking calcium combined with vitamin D, as well as a reduced risk of hip fractures. However, the benefits were more pronounced in women who were most compliant with supplement dosing and those over 60 years old.
A recent study found that older women are more susceptible to hip fractures, with over half experiencing significant decline in functioning. Unfortunately, many women in this age group do not undergo bone density screenings, which can help prevent fractures through osteoporosis therapy.
Researchers found that a four-year study combining weight-bearing exercise and calcium supplementation increased bone mineral density in women by 1-2%, reversing typical loss of BMD with age. The regimen, developed for the BEST Study, includes six core exercises to build bone in key fracture sites.
Researchers have identified vitamin D as a potential target for preventing bone loss and osteoporosis. The study suggests that vitamin D may signal anti-osteoclastogenic action, which could lead to new treatments for this condition.
Researchers reviewed 35 patients taking glucocorticoids for chronic skin diseases. The study found that only 20% were taking bisphosphonates, a medication proven to prevent glucocorticoid-induced osteoporosis. The authors recommend prescribing bisphosphonates concomitantly with corticosteroid therapy in certain cases.
Researchers discovered that substances produced in the body called endocannabinoids, which are present in bones and other tissues, help preserve bone density. A new synthetic compound has been developed to activate CB2 receptors, slowing osteoporosis development without psychoactive side effects.
Researchers have discovered that cannabinoid receptors, particularly CB2, play a crucial role in regulating bone density and reducing the risk of osteoporosis. The study found that mice with a specific gene defect exhibit lower bone density, while patients carrying a variant of the CB2 gene have a three-fold higher risk of osteoporosis.
A Mayo Clinic study found that vertebroplasty significantly improved back pain and activity levels in patients with vertebral compression fractures. Patients' pain during rest and activity improved an average of seven points one week after treatment and remained improved for up to a year.
Researchers found that risedronate therapy significantly reduced plaque and improved periodontal status in postmenopausal women with osteoporosis. The study also highlighted the link between osteoporosis and periodontal disease, suggesting similar treatment and management may minimize tooth loss.
A Phase 2 trial of denosumab found significant increases in bone mineral density across various sites, including the lumbar spine, total hip, and distal radius. The study suggests denosumab may offer a new approach to treating osteoporosis by targeting RANK Ligand.
Five organizations have won US$10,000 each for imaginative education projects focused on osteoporosis prevention and management. These grants will support public education materials, campaigns, and awareness initiatives across Indonesia, Iran, Jordan, Panama, and Taiwan.
The event aimed to raise awareness about the importance of maintaining strong bones, particularly for young people, who can build peak bone mass between ages 11-17. Experts stressed the need for proper diet, exercise, and lifestyle habits to reduce the risk of osteoporosis, which affects one in three women over 50 worldwide.
Researchers propose a two-stage screening approach to identify individuals with low bone mineral density and increased risk of osteoporotic fractures. This could lead to improved cost-effectiveness in treatment, reducing the economic burden of fractures on individuals and society.
Researchers at UCLA used a drug to block mutant proteins from deforming cell nuclei, significantly reducing misshapen nuclei in human cells. The findings offer new clues into how progeria develops and could lead to treatment with new drugs for related disorders like osteoporosis.
A Purdue study found that increasing calcium intake by 200-300mg per day can significantly boost bone mineral density in young women taking oral contraceptives, reducing the risk of osteoporosis. The researchers suggest that this simple change can prevent a significant loss of bone mass, particularly during peak bone development years.
A new study shows that combining parathyroid hormone and alendronate for a year followed by a year increases bone density significantly more than other treatments, providing sustained gains. The treatment has the potential to offer the largest gains in bone density yet available at a lower cost than using parathyroid hormone alone.
Standard clinical practice guidelines often focus on one disease and exclude coexisting conditions, leaving clinicians without guidance for caring for older patients with multiple chronic diseases. This can lead to polypharmacy, medication errors, and an unsustainable treatment burden.
Vertebroplasty and kyphoplasty treatments offer pain relief for osteoporosis sufferers, with the National Osteoporosis Foundation estimating 44 million Americans over 50 affected. The procedures stabilize fractured bones and prevent movement, providing significant cost savings.
A study published in JAMA found that black women had a significantly lower risk of fractures than white women at every level of bone mineral density. Despite this, researchers emphasize the importance of considering individual factors such as body weight and other risk factors when assessing fracture risk.
A study found that 1 in 6 elderly patients with clinically important vertebral fractures had unreported osteoporosis diagnoses, highlighting the need for better screening and treatment strategies.
Researchers found that a peptide called GPCS significantly inhibited bone mineral loss in isolated bone cells from newborn rats. Additional studies are needed to determine the mechanism of action and effectiveness of GPCS on human bone health.
Researchers at Yale University identified IRAK-M as a key regulator of bone cells, finding that its presence prevents bone loss and its absence leads to severe osteoporosis in mice. The study suggests IRAK-M could be a new target for treating or preventing osteoporosis.
A study shows that lidocaine patch 5% and celecoxib achieved significant reductions in pain intensity, with 62% of patients in the celecoxib group experiencing a 30% or greater improvement. The findings offer hope for OA patients seeking alternative pain relief options.
A study of strict raw food vegans found they had lower body mass indices and significantly lower bone mass, but normal markers of bone turnover. They also had higher-than-normal vitamin D levels and low inflammation.
A recent study suggests that patients with osteoporosis may have coexisting celiac disease, which can lead to impaired calcium and vitamin D absorption. Screening for celiac disease in patients with osteoporosis may be recommended to correct bone loss.
Researchers found that patients with osteoporosis had a significantly higher prevalence of celiac disease than those without osteoporosis. Treatment with a gluten-free diet resulted in improved bone mineral density in individuals with celiac disease and osteoporosis, making serologic screening worthwhile for this population.
A recent study of 1,323 women reveals a significant gap in osteoporosis treatment based on fracture history. Women with past fractures are at a higher risk of future osteoporosis, emphasizing the importance of considering fracture history in treatment decisions.
Research demonstrates that the sympathetic nervous system mediates bone resorption through a receptor on bone cells, which is required for osteoporosis development. Preventing this effect could lead to the prevention of osteoporosis. Drugs like beta blockers show promise in reducing fractures and may be repurposed to target bone health.
Researchers at the Friedman School of Nutrition Science and Policy at Tufts University have identified two variants in the perilipin gene associated with increased obesity risk in white women. Vitamin B12 deficiency has also been linked to lower bone mineral density, increasing the risk of osteoporosis.
Researchers found a genetic variant of the CYP1A1 gene associated with lower estrogen levels, higher bone resorption markers, and lower bone density in hip bones. This variant may serve as an important genetic marker for identifying women at high risk of osteoporosis.